Recent share performance and business snapshot

Haemonetics (HAE) shares have retreated over the past 3 months, with the price closing at $55.93 and total return showing declines over the week, month, past 3 months, year and year to date.

The Boston based medical technology company generates US$1.32b in revenue and US$175.44m in net income, with operations spanning plasma collection systems, hospital hemostasis analyzers, blood recovery products and vascular closure devices.

The recent 30.10% 3‑month share price return decline and 30.07% year‑to‑date share price return decline, alongside a 12.95% 1‑year total shareholder return decline and 49.62% 5‑year total shareholder return decline, suggest momentum has been fading and investors are reassessing Haemonetics' risk and growth profile.

If you are comparing Haemonetics with other healthcare related opportunities, it could be useful to scan a focused list of 36 healthcare AI stocks

With Haemonetics trading at US$55.93 at what appears to be a discount to both analyst targets and intrinsic value estimates, you have to ask: is this sustained weakness a potential entry point, or is the market already factoring in future growth?

Most Popular Narrative: 36.4% Undervalued

Haemonetics' most followed narrative sets a fair value of $88.00 against the recent $55.93 close, framing a sizeable valuation gap that rests on execution in plasma and hospital technologies.

Rapid innovation and increased adoption of advanced plasma collection systems (NexSys with Persona and Express Plus), as well as new software contracts securing ~80% market share, are driving share gains and supporting double-digit organic growth ex-CSL in the plasma segment. These trends are expected to boost both revenue and net margins as upgrades and center conversions accelerate through FY26 and into FY27.

Curious what kind of revenue mix, margin profile, and future earnings multiple need to line up to support that $88.00 figure? The narrative leans heavily on plasma, hospital software and interventional growth all working together, plus a specific return hurdle that shapes the present value story.

Result: Fair Value of $88.00 (UNDERVALUED)

However, this hinges on execution, with competition in vascular closure and reliance on NexSys, TEG and VASCADE in the U.S. all capable of disrupting that $88.00 narrative.

Next Steps

Seeing mixed signals on value and execution risks today, you might want to move quickly and test the thesis against the full balance of 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Haemonetics has your attention but you want a broader watchlist, now is the time to widen the net and pressure test your next moves.

• Target potential mispricings by scanning companies trading below what their fundamentals may justify using the 55 high quality undervalued stocks
• Prioritize resilience and downside protection by focusing on businesses identified in the 74 resilient stocks with low risk scores
• Hunt for lesser known opportunities with solid fundamentals by reviewing the screener containing 25 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.